PURIFICATION AND CHARACTERIZATION OF INFLUENZA A VIRUS INHIBITORS IN ANIMAL SERA
动物血清中甲型流感病毒抑制剂的纯化和表征
基本信息
- 批准号:03670234
- 负责人:
- 金额:$ 1.28万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1991
- 资助国家:日本
- 起止时间:1991 至 1992
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Normal horse and guinea pig sera contain a2-macroglobulin which inhibits the infectivity and hemagglutinating activity of influenza A viruses of the H2 and H3 subtypes. On the other hand, normal bovine serum contains a component termed beta inhibitor that inhibits the infectivity and hemagglutinating activity on influenza A viruses of the H1 and H3 subtypes. To investigate the nature of the beta inhibitor of influenza A virus, we purified the conglutinin and examined its characteristics. The conglutinin , purified from bovine serum, had neutralizing-activity as well as HI activity on influenza A viruses of the H1 and H3 subtypes. The HI activity of conglutinin was heat stable, Ca^<++>-dependent, and resistant to both neuraminidase and periodate treatments. The HI activity of purified conglutinin was blocked by N-acetylglucosamine but not by D- mannose. The conglutinin was bound to hemagglutinin which had high mannose and complex sugar chains and its binding was inhibited by N- acetylglucosamine and dependent on devalent cations. These data indicate that the beta-like inhibitor activity of bovine serum is mainly dependent on conglutinin which inhibits hemagglutination and neutralizes the virus infectivity by its binding to a carbohydrate site at the HA. Nextly, we tried to clone the cDNA coding for bovine conglutinin. cDNA clones encoding the bovine conglutinin were isolated from a bovine liver cDNA library using a specific probe obtained from the PCR product. These cDNAs carry an insert of 1113 bp coding for a protein of 371 amino acid residues with a signal peptide of 20 residues. Southern blot analysis of total bovine genomic DNA indicated that there is only one copy of the gene encoding bovine conglutinin. Northern blot analysis of bovine tissues showed that conglutinin mRNA of about 1.5 kb is expressed in the liver and also slightly in the lung.
正常的马和豚鼠血清含有α 2-巨球蛋白,其抑制甲型流感病毒H2和H3亚型的感染性和血凝活性。另一方面,正常牛血清含有称为β抑制剂的组分,其抑制对H1和H3亚型甲型流感病毒的感染性和血凝活性。为了研究A型流感病毒β抑制剂的性质,我们纯化了连接蛋白并检测了其特性。从牛血清中纯化的连接蛋白对H1和H3亚型的A型流感病毒具有中和活性和HI活性。刀豆素的HI活性是热稳定的,Ca^++依赖的,并且对神经氨酸酶和高碘酸盐处理都有抗性。纯化后的刀豆素的HI活性可被N-乙酰氨基葡萄糖阻断,但不被D-甘露糖阻断。结合蛋白与血凝素结合,血凝素具有高甘露糖和复杂的糖链,其结合被N-乙酰氨基葡萄糖抑制,并依赖于低价阳离子。这些数据表明,牛血清的β-样抑制剂活性主要依赖于抑制血凝并通过与HA上的碳水化合物位点结合来中和病毒感染性的补体。其次,我们试图克隆编码牛conglutinin的cDNA。使用从PCR产物获得的特异性探针,从牛肝cDNA文库中分离编码牛连接蛋白的cDNA克隆。这些cDNA携带1113 bp的插入片段,编码371个氨基酸残基的蛋白质,其中20个残基为信号肽。对牛基因组DNA的Southern杂交分析表明,编码牛conglutinin的基因只有一个拷贝。牛组织的北方印迹分析表明,约1.5 kb的conglutinmRNA在肝中表达,在肺中也有少量表达。
项目成果
期刊论文数量(25)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Y.Suzuki,Y-P.Yin,M.Makino,T.Kurimura,N.Wakamiya: "Cloning and sequencing of a cDNA coding for bovine conglutinin" Biochemical Biophysical Research Communications.
Y.Suzuki、Y-P.Yin、M.Makino、T.Kurimura、N.Wakamiya:“牛凝集素 cDNA 编码的克隆和测序”生物化学生物物理研究通讯。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N.WAKAMIYA,Y.OKUNO,F.SASAO,S.UEDA,K.YOSHIMATSU,M.NAIKI,T.KURIMURA: "ISOLATION AND CHARACTERIZATION OF CONGLUTININ AS AN INFLUENZA A VIRUS INHIBITOR" BIOCHEM. BIOPHYS. RES. COMMUN. 187. 1270-1278 (1992)
N.WAKAMIYA、Y.OKUNO、F.SASAO、S.UEDA、K.YOSHIMATSU、M.NAIKI、T.Kurimura:“球凝素作为流感病毒抑制剂的分离和表征”生物化学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.ASAOKA,S.NISHINAKA,N.WAKAMIYA,H.MATSUDA,M.MURATA: "TWO CHICKEN MONOCLONAL ANTIBODIES SPECIFIC FOR HETEROPHIL HANGANUTZIU-DEICHER ANTIGENS" IMMUNOLOGY LETTERS. 32. 91-96 (1992)
H.ASAOKA、S.NISHINAKA、N.WAKAMIYA、H.MATSUDA、M.MURATA:“两种针对异嗜 HANGANUTZIU-DEICHER 抗原特异的鸡单克隆抗体”免疫学信件。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
T.Nishimura,Y.Togashi,N.Wakamiya,Y.Hashimoto,H.Yagita,K.Okumura,S.Habu: "Tcell receptor-independent cell-mediated cytotoxicity by nude mouse lymphokeine-activated killer cells" Japan Journal of Cancer Research(Gann). 82. 448-455 (1991)
T.Nishimura,Y.Togashi,N.Wakamiya,Y.Hashimoto,H.Yagita,K.Okumura,S.Habu:“裸鼠淋巴因子激活杀伤细胞的T细胞受体独立细胞介导的细胞毒性”日本癌症杂志
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N.Wakamiya,Y.Osada,D.Q.Wang,K.Nakajima,S.Kato,T.Kurimura,M.Naiki.: "Expression of HanganutziuーDeicher antigen in activated human T lymphocytes" Biochemical Biophysical Research Communications. 81. 310-315 (1991)
N. Wakamiya、Y. Osada、D. Q. Wang、K. Nakajima、S. Kato、T. Kurimura、M. Naiki.:“Hanganutziu-Deicher 抗原在活化的人 T 淋巴细胞中的表达”生化生物物理研究通讯。 315 (1991)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAKAMIYA Nobutaka其他文献
WAKAMIYA Nobutaka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAKAMIYA Nobutaka', 18)}}的其他基金
Study of Kawasaki Disease
川崎病的研究
- 批准号:
26670489 - 财政年份:2014
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Basic study of evaluation system in vascular diseases
血管疾病评价体系的基础研究
- 批准号:
22390113 - 财政年份:2010
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic analysis of new collectins in renal tract.
肾道新集合素的基础分析。
- 批准号:
19390227 - 财政年份:2006
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Study of analysis for vascular damage due to embolism and inflammation
栓塞和炎症引起的血管损伤分析研究
- 批准号:
16390161 - 财政年份:2004
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The study on functions on the membrane type collectm CL-P1 in vascular cells.
血管细胞膜型collectm CL-P1的功能研究。
- 批准号:
13470139 - 财政年份:2001
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The relationship between the stress and serum mannan-binding lectin.
应激与血清甘露聚糖结合凝集素之间的关系。
- 批准号:
09672356 - 财政年份:1997
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
丹参酮ⅡA联合miR-29b inhibitor调控TGF-β1 / Smad3协同促进肌腱功能修复的机制研究
- 批准号:81702135
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
石斑鱼凋亡抑制因子Bax inhibitor 1(BI-1)在虹彩病毒SGIV侵染中的功能研究
- 批准号:31402335
- 批准年份:2014
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
马铃薯invertase inhibitor基因克隆及抗低温糖化品质改良
- 批准号:30270842
- 批准年份:2002
- 资助金额:20.0 万元
- 项目类别:面上项目
C1-Inhibitor在真核细胞中表达的研究
- 批准号:39270620
- 批准年份:1992
- 资助金额:4.0 万元
- 项目类别:面上项目
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
敗血症におけるplasminogen activator inhibitor-1阻害の効果検証
验证纤溶酶原激活剂抑制剂-1 抑制在脓毒症中的有效性
- 批准号:
24K02544 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CCA's lineage heterogeneity and subsequent adaptive reprogramming upon acquired resistant to CDK4/6 inhibitor.
CCA 的谱系异质性以及随后获得对 CDK4/6 抑制剂耐药性后的适应性重编程。
- 批准号:
24K18491 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
FMO/ML-Guided Drug Design: Accelerating Novel Inhibitor Development and Drug Discovery
FMO/ML 引导的药物设计:加速新型抑制剂的开发和药物发现
- 批准号:
24K20888 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a Cathepsin V inhibitor for application as an anti-tumour agent.
开发用作抗肿瘤剂的组织蛋白酶 V 抑制剂。
- 批准号:
MR/Y503447/1 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Research Grant
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Continuing Grant
大腿骨頭壊死に対するSclerostin inhibitorによる骨再生の検討
使用 Sclerostin 抑制剂检查股骨头坏死骨再生
- 批准号:
24K12348 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.
STX-002的适应症选择、患者分层和IND准备:用于治疗慢性肾病和免疫治疗耐药肿瘤的一流LRG1抑制剂。
- 批准号:
10092585 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Collaborative R&D
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
- 批准号:
10750132 - 财政年份:2024
- 资助金额:
$ 1.28万 - 项目类别:
Identification of novel therapeutic target and mechanism for PARP inhibitor combination therapy
PARP抑制剂联合治疗的新治疗靶点和机制的鉴定
- 批准号:
23K08100 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)